Scilex Holding (SCLX) Cost of Revenue (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Cost of Revenue of $4.4 million for Q1 2026, up 221.32% year-over-year from $1.4 million in Q1 2025, and up 70.12% on a QoQ basis from $2.6 million in Q4 2025.
Scilex Holding (SCLX) Cost of Revenue (2022 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Cost of Revenue for 5 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue rose 221.32% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $13.7 million (down 4.01% YoY), while the FY2025 annual figure was $10.6 million, down 36.49% from the prior year.
- Cost of Revenue came in at $4.4 million for Q1 2026 at Scilex Holding, up from $2.6 million in the prior quarter.
- The five-year high for Cost of Revenue was $4.7 million in Q4 2024, with the low at $1.1 million in Q1 2022.
- Average Cost of Revenue over 5 years is $3.4 million, with a median of $3.6 million recorded in 2022.
- Across the five-year window, Cost of Revenue sank 63.96% in 2025 and jumped 221.32% in 2026, its largest moves.
- Year by year, Cost of Revenue stood at $4.5 million in 2022, then increased by 0.18% to $4.5 million in 2023, then rose by 3.76% to $4.7 million in 2024, then slumped by 44.28% to $2.6 million in 2025, then soared by 70.12% to $4.4 million in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $4.4 million, $2.6 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.58 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 8.11 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 4.22 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 2.68 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 4.20 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.74 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 1.45 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 3.55 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.45 Mn |
| Mar 31, 2026 | 4.45 Mn |
| Dec 31, 2025 | 2.61 Mn |
| Dec 31, 2025 | 2.61 Mn |
| Sep 30, 2025 | 3.33 Mn |
| Sep 30, 2025 | 3.33 Mn |
| Jun 30, 2025 | 3.27 Mn |
| Jun 30, 2025 | 3.27 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Sep 30, 2024 | 3.77 Mn |
| Sep 30, 2024 | 3.77 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Mar 31, 2024 | 3.84 Mn |
| Mar 31, 2024 | 3.84 Mn |
| Dec 31, 2023 | 4.52 Mn |
| Dec 31, 2023 | 4.52 Mn |